Overview

A Bioequivalence Study Comparing Two Different Tafamidis Formulations

Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
Each subject will be given tafamidis. After swallowing a single tafamidis capsule, tafamidis blood concentrations will be measured periodically for one week. After about 20 days, subjects will take a different form of tafamidis capsule and the process repeated. Tafamidis concentrations from the two different formulations will be compared to determine if they are approximately the same.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer